atrial fibrillation - antithrombotics - secondary prevention of thromboembolic events clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>atrial fibrillation</strong> - antithrombotics </a> - secondary prevention of thromboembolic events trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> EAFT, 1993 </a> <br> </td> <td> Oral anticoagulation standard dose(target INR 3.0 (2.5-4.0)) the choice of anticoagulant type was free but most physicians choose coumarin derivatives.<br>  <i>versus</i> <br> placebo </td> <td> Patient with non rheumatic AF and recent TIA or minor ischaemic stroke(secondary prevention). </td> <td> follow-up 2.3 years<br> n=225/214<br> Parallel groups<br> Open <br> </td> </tr> <tr> <td> <a href="index.html"> EAFT, 1993 </a> <br> </td> <td> aspirin 300 mg/d<br>  <i>versus</i> <br> placebo </td> <td> Patient with non rheumatic AF and recent TIA or minor ischaemic stroke(secondary prevention). </td> <td> follow-up 2.3 years<br> n=404/378<br> Parallel groups<br> Double blind <br> europe,israel </td> </tr> <tr> <td> <a href="index.html"> SIFA, 1997 </a> <br> NCT00244426 </td> <td> indobufen 200 mg (the dose was lowered to 100 mg if impaired renal function:cc<80 ml/mn)<br>  <i>versus</i> <br> warfarin standard dose(target INR 2.0-3.5) </td> <td> non rhumatismal AF and recent cerebral ischemic episode(< or =15 days) </td> <td> follow-up 12 months<br> n=462/454<br> Parallel groups<br> Open <br> Italy </td> </tr> <tr> <td> <a href="index.html"> FFAACS , 2001 </a> <br> </td> <td> fluidione standard dose (target INR: 2-2.6) + aspirin low dose 100 mg<br>  <i>versus</i> <br> fluidione standard dose(target INR:2-2.6) + placebo </td> <td> high risk patients with non valvular atrial fibrillation </td> <td> follow-up 0.84 y<br> n=76/81<br> Parallel groups<br> Double blind <br> France </td> </tr> <tr> <td> <a href="index.html"> RE-LY 150mg subgroup, </a> <br> </td> <td> dabigatran 150mg daily<br>  <i>versus</i> <br> warfarin </td> <td> patients with a prior stroke or transient ischemic attack </td> <td> follow-up 2 y<br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> RE-LY 110mg subgroup, 2010 </a> <br> </td> <td> dabigatran 110mg daily <br>  <i>versus</i> <br> warfarin </td> <td> patients with a prior stroke or transient ischemic attack </td> <td> follow-up 2 y<br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> </table> <h2>References</h2> <p> <b>EAFT, 1993 : </b> Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. <i>Lancet. 1993 Nov 20;342(8882):1255-62</i> [PMID 7901582] </p> <p> <b>SPINAF, 1992 : </b> Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJWarfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. <i>N Engl J Med 1992 Nov 12;327:1406-12</i> [PMID 1406859] </p> <p> <b>EAFT, 1993 : </b> Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. <i>Lancet. 1993 Nov 20;342(8882):1255-62</i> [PMID 7901582] </p> <p> <b>UK-TIA(high dose), 1991 : </b> Farrell B, Godwin J, Richards S, Warlow CThe United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. <i>J Neurol Neurosurg Psychiatry 1991 Dec;54:1044-54</i> [PMID 1783914] </p> <p> <b>UK-TIA(low dose), 1991 : </b> Farrell B, Godwin J, Richards S, Warlow CThe United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. <i>J Neurol Neurosurg Psychiatry 1991 Dec;54:1044-54</i> [PMID 1783914] </p> <p> <b>ESPS II, 1996 : </b> Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal AEuropean Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. <i>J Neurol Sci 1996 Nov;143:1-13</i> [PMID 8981292] </p> <p> <b>SIFA, 1997 : </b> Morocutti C, Amabile G, Fattapposta F, Nicolosi A, Matteoli S, Trappolini M, Cataldo G, Milanesi G, Lavezzari M, Pamparana F, Coccheri SIndobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. <i>Stroke 1997 May;28:1015-21</i> [PMID 9158644] </p> <p> <b>EAFT, 1993 : </b> Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) <i>Lancet. 1993 Nov 20;342(8882):1255-62</i> [PMID 7901582] </p> <p> <b>NASPEAF, 2004 : </b> Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, Mataix LComparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. <i>J Am Coll Cardiol 2004 Oct 19;44:1557-66</i> [PMID 15489085] </p> <p> <b>FFAACS , 2001 : </b> Lechat P, Lardoux H, Mallet A, Sanchez P, Derumeaux G, Lecompte T, Maillard L, Mas JL, Mentre F, Pousset F, Lacomblez L, Pisica G, Solbes-Latourette S, Raynaud P, Chaumet-Riffaud PAnticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS). <i>Cerebrovasc Dis 2001;12:245-52</i> [PMID 11641591] </p> <p> <b>RE-LY 150mg subgroup, : </b> 1.Diener HC, Connolly S, Ezekowitz MD, et al.Dabigatran compared to warfarin in patients with atrial fibrillation and prior TIA or stroke: Results of RE-LY <i>American Stroke Association International Stroke Conference 2010; February 26, 2010; San Antonio, TX. Abstract 195</i> [PMID ] </p> <p> <b>RE-LY 110mg subgroup, 2010 : </b> 1.Diener HC, Connolly S, Ezekowitz MD, et al.Dabigatran compared to warfarin in patients with atrial fibrillation and prior TIA or stroke: Results of RE-LY <i>American Stroke Association International Stroke Conference 2010; February 26, 2010; San Antonio, TX. Abstract 195</i> [PMID ] </p>